DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
Zacks.com on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...
(NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults ...
These healthcare stocks have long-term and profitable growth runways.
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been ...
Since last year, DexCom ( DXCM +5.54%) has faced a series of issues that have sunk its stock price. The medical device ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. | Dexcom said Smart Basal is the ...
DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback